Open Access

A novel self-micro-emulsifying delivery system (SMEDS) formulation significantly improves the fasting absorption of EPA and DHA from a single dose of an omega-3 ethyl ester concentrate

Lipids in Health and Disease201716:204

https://doi.org/10.1186/s12944-017-0589-0

Received: 3 August 2017

Accepted: 3 October 2017

Published: 16 October 2017

Abstract

Background

Absorption of EPA and DHA from Omega-3-acid ethyl ester (EE) concentrate supplements occurs most efficiently when taken in context of a fatty meal; adequate fat intake is required to release bile salts that emulsify and pancreatic enzymes that digest omega-3-containing lipids in the intestine. Current guidelines recommend reduction in fat intake and therefore there is a need to optimize the absorption of Omega-3 in those consuming low-fat or no-fat meals. To this end, BASF has developed an Absorption Acceleration Technology, a novel self-micro-emulsifying delivery system (SMEDS) formulation of highly concentrated Omega-3-acid EE which enables rapid emulsification and microdroplet formation upon entering the aqueous environment of the gut therefore enhances the absorption.

Methods

Two separate single dose, crossover studies were conducted to determine the relative bioavailability of omega-3-acid EE concentrate, either as a novel SMEDS formulation (PRF-021) or as control, in healthy fasted male and female adults at two dose levels (Study 1 “low dose”: 630 mg EPA + DHA in PRF-021 vs. 840 mg EPA + DHA in control; Study 2 “high dose”: 1680 mg EPA + DHA in PRF-021 vs. 3360 mg EPA + DHA in control). Blood samples were collected immediately before supplementation and at defined time intervals for 48 h. Plasma concentration of total EPA and DHA were determined for pharmacokinetic analysis, area under the curve (AUC) and maximum observed concentration (Cmax) was determined.

Results

Total EPA plus DHA absorption from SMEDS formulation PRF-021 were 6.4 and 11.5 times higher compared to control in low- and high-dose studies respectively, determined as the ratio of baseline corrected, dose normalized AUC0-24h of PRF-021 over that of control. EPA and DHA individually showed differing levels of enhancement: the AUC0-24h ratio for EPA was 23.8 and 25.7 in low and high dose studies, respectively, and the AUC0-24h ratio for DHA was 3.6 and 5.6 in low and high dose studies, respectively. Cmax was also increased for both EPA and DHA 2.7- to 9.2-fold.

Conclusion

PRF-021 is a novel SMEDS formulation of Omega-3-acid EE demonstrating a marked improvement in absorption of a single dose of EPA and DHA EE under fasted conditions. This allows adequate absorption of Omega-3 from the supplement without the requirement of a high-fat meal.

Keywords

Omega-3-acid ethyl ester (EE)Eicosapentaenoic acid (EPA)Docosahexaenoic acid (DHA)Self-micro emulsifying delivery system (SMEDS)AbsorptionBioavailability

Background

Omega-3 fatty acids integrate into cell membranes of every cell type in the body, and supplemental Omega-3 lipids have been studied with respect to a variety of health promoting activities, in disparate bodily systems such as brain, eye, skin, musculoskeletal, joint, and cardiovascular. Delivery of Omega-3 fatty acids to each of these cell types requires adequate delivery to the bloodstream, pointing to the need to optimize their bioavailability.

For example, the importance of bioavailability is evident regarding supplementation of Omega-3 lipids for cardiovascular health. Strong epidemiologic evidence points to the cardiovascular health benefit of higher intake, blood levels, and cellular stores of Omega-3 fatty acids, specifically EPA and DHA [15]. Recent reviews and meta-analyses confirm the effectiveness of Omega-3 treatment in risk reduction of secondary cardiovascular outcomes [68]. Nevertheless, recent clinical trials have reached neutral conclusions with respect to primary cardiovascular outcomes in the use of Omega-3 supplementation in risk reduction of cardiovascular disease [9, 10]. One hypothesis attempting to explain this discrepancy is that Omega-3 supplement bioavailability was not optimized during study design, for example, due to the lack of recommendations to take supplements with a high-fat meal [4].

Optimal absorption of Omega-3 fatty acid supplements occur with intake of a fat-containing meal due to stimulation of bile release as reviewed by Schuchardt [11]. The impact of bile secretion is two-fold: 1) bile acids promote emulsification of the fats to microdroplets to allow adequate access to digestive enzymes, and 2) pancreatic digestive enzyme hydrolyze the fats to fatty acids and monoglycerides which are then available for intestinal absorption.

It is not always desired or convenient to take supplements with a fatty meal, and in addition, those at risk of heart disease are counseled to reduce animal fat intake [12]. To promote greater absorption of Omega-3 without a high fat meal, it is possible to simulate the emulsification function of bile release by designing a self-micro-emulsifying delivery system (SMEDS). To this end, we have designed an Absorption Accelerating Technology: a proprietary SMEDS Omega-3 technology (specific formulation PRF-021) (Fig. 1) which is a liquid softgel containing highly concentrated Omega-3 ethyl esters, food-grade carrier oils, emulsifiers, and antioxidants which are spontaneously emulsified to microdroplets in the gastric contents.
Fig. 1

Absorption accelerating technology

The present paper presents the results of two studies designed to compare the bioavailability of a single dose of Omega-3 SMEDS formulation PRF-021 to its parent high concentrate Omega-3 ethyl ester oil at two dosage amounts in healthy, fasted subjects.

Methods

Study design and procedures

Two separate studies were conducted at Covance Clinical Research Unit (CRU). Both trials are open-label, randomized, cross-over single dose studies.

Study 1 was conducted in Allschwil, Switzerland and Study 2 in Leeds, U.K. Prior to the start of the study, the protocol and Informed Consent Form were reviewed and approved by the local Ethics Committee (EC). The study commenced after receipt of a EC approval. The regulatory permission to perform the study was obtained in accordance with applicable regulatory requirements. All ethical and regulatory approvals were available before a subject was exposed to any study-related procedure. The studies were conducted in accordance with Covance standards meeting requirements of Good Clinical Practice guidelines, the Declaration of Helsinki and local laws. Each subject was given a volunteer information, which provided details on the investigational products, procedures and potential risks involved and all subjects were given the option to obtain further information from the Investigator. A written informed consent was obtained from all subjects before they entered the study. Subjects were not permitted to take any medication, herbal products, omega-3 fatty acid supplements or fish oil preparations within 14 days before the first dose of the study. Subjects were instructed not to eat more than one fatty fish meal per week within this 14-day period. Vitamins and mineral supplements not containing omega-3 fatty acids or fish oil and non-containing other substances were allowed until 48 h before each dose.

Participants

A total of 20 and 40 subjects were randomized in Study 1 and 2, respectively. One subject was withdrawn in the PRF-021 treatment in Study 2, so a total of 20 and 39 subjects finished in Study 1 and 2, respectively. In both trials, healthy adult subjects of any ethnic origin, aged between 18 and 55 years, with a body mass index (BMI) between 18.5 and 30.0 kg/m2, were selected. From 14 days before the administration of the first dose until completion of the post study visit, subjects were required to eat no more than 1 fish meal per week and to avoid taking fish oil or omega-3-fatty acids supplements. There were also limitations for intake of poppy seeds, Seville oranges, grapefruit and caffeine containing foods and beverages. Summary of main demographic data is listed in Table 1.
Table 1

Summary of screening demographic data in Study 1 and 2

 

Study 1

Study 2

Overall

N = 20

N = 40

Age (years)

45 (24–55)

31 (19–55)

Male

17 (85.0%)

20 (50.0%)

Female

3 (15.0%)

20 (50.0%)

Race white

19 (95.0%)

38 (95.0%)

Race non-white

1 (5.0%)

2 (5.0%)

Ethnicity Hispanic or Latino

1 (5.0%)

1 (2.5%)

Not Hispanic or Latino

19 (95.0%)

39 (97.5%)

Weight (kg)

82.2 (56.3–98.6)

70.9 (47.3–105.8)

BMI (kg/m2)

26.8 (22.3–29.4)

23.5 (18.5–29.3)

Data presented as average (min-max), or participant numbers (percentage)

Dosing

Each treatment period consisted of an in-clinic stay at the unit lasting from Day −1 (the evening before dosing) to Day 3 (48 h post-dose). On each dosing occasion, subjects fasted for at least 10 h overnight before dosing and approximately 4.5 h after dosing, when a standard low-fat (<15 g total fat content) lunch was given. Each subject swallowed the appropriate number of capsules with approximately 240 mL of water at room temperature. Subjects were not allowed any other intake of fluids from 1 h prior to until 2 h after dosing. Standard meals designed for bioavailability studies not containing fish were provided for all subjects whilst resident in the clinical research unit. In both studies, after an initial washout period, subjects were randomized to either a PRF-021 or control with a crossover washout period of at least 6 treatment-free days between each treatment. A crossover design was chosen in both studies to give a within-subject assessment of the absorption of EPA and DHA and to increase the power of the study for the given number of subjects. The evaluated omega-3 fatty acids EPA and DHA are dietary compounds for which quantifiable endogenous plasma levels are to be expected in healthy subjects. In prior studies at similar doses (data on file), the EPA and DHA levels were back to the baseline value by about 48 h after dosing. Hence, a washout period of at least 6 treatment-free days (the first treatment-free day started 24 h after the dosing time) between each study treatment is considered appropriate for practical reasons, and sufficient to avoid carry-over effects.

Omega-3 (EPA and DHA) content of each supplement group is given in Table 2. In Study 1, subjects were given two SMEDS-formulated PRF-021 capsules (total dosage: 630 mg EPA + DHA) or one control Omega-3 ethyl ester concentrate capsule (dosage: 840 mg EPA + DHA). In Study 2, subjects were given four SMEDS-formulated PRF-021 capsules (total dosage: 1680 mg EPA + DHA) or four control Omega-3 ethyl ester concentrate capsules (total dosage: 3360 mg EPA + DHA).
Table 2

Nominal EPA and DHA doses in Study 1 and 2

Study

Omega-3

PRF-021

Control

Per capsule (mg)

Capsules (#)

Per treatment (mg)

Per capsule (mg)

Capsules (#)

Per treatment (mg)

1. Low dose

EPA-EE

173

 

345

460

 

460

DHA-EE

142

2

285

380

1

380

EPA + DHA EE

315

 

630

840

 

840

2. High dose

EPA-EE

230

 

920

460

 

1840

DHA-EE

190

4

760

380

4

1520

EPA + DHA EE

420

 

1680

840

 

3360

PRF-021 features Absorption Acceleration Technology, which is a proprietary of ultra-high-concentration fish oil ethyl esters (>80% EPA + DHA) with food-grade excipients - carrier oils, antioxidants, and emulsifiers - designed to promote the spontaneous formation of micron-sized microdroplets in simulated gastric and intestinal fluids and optimized degradation by digestive enzymes (BASF internal data). An extensive number of different formulations were screened by the in vitro system thereafter a selected number were included in non-clinical bioavailability assessment. Bioavailability of the formulations were verified in a minipig absorption model (BASF internal data).

In Study 1, the lower dose administration range (less than 1000 mg of EPA + DHA) with lower variability was chosen to facilitate the comparison between PRF-021 and control within a dose range applicable for dietary supplement use. From a prior study (data not shown) where the control Omega-3 concentrate was administered as a 1000 mg single oral dose, the inter-individual coefficient of variance (CV%) of DHA, AUC and Cmax, were taken as a reference for the sample size calculation of this study. A sample size of 20 subjects (per treatment) was determined to provide the study a statistical power of 80% to demonstrate a difference in AUC in PRF-021 and control of more than 25% and an alpha level of 0.05. In the subsequent Study 2, the absorption comparison between PRF-021 and control was conducted at higher uptake level range (1000–4000 mg of sum EPA EE plus DHA EE) with expected higher variability, the sample size was increased to 40 individuals to achieve the above statistical analytical power.

Blood samples collection and determination of EPA and DHA

In both studies, blood samples were drawn immediately before administration of the test product and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24 and 48 h’ post-dose. In Study 2, two additional blood samples were drawn at 1.5 and 36 h’ post-dose. Plasma were prepared within 2 h of blood withdrawal and stored at −80 °C until analysis.

The total EPA and DHA analysis in plasma samples were conducted in Study 1 by AS Vitas, Norway and in Study 2 by the Department of Bioanalysis and Immunology, Charles River Laboratories, Edinburgh UK. The samples were analyzed with validated chromatographic methods; gas chromatography with flame ionization detection (GC-FID) method in Study 1 and high performance liquid chromatography-mass/mass (HPLC-MS/MS) method in Study 2. The limit of quantification of total EPA and DHA in plasma is 5 μg/ml for both methods.

The EPA-EE and DHA-EE in plasma samples were analyzed with validated HPLC-MS/MS method. The limit of quantification of EPA-EE and DHA-EE is 20 ng/mL.

Pharmacokinetic analyses

The pharmacokinetic parameters were determined using non-compartmental analysis from the plasma concentrations of EPA and DHA. The area under the plasma concentration-time curve (AUC) was calculated by applying the log-linear trapezoidal model to the measured EPA and DHA concentrations and the combined sum of EPA plus DHA at the actual sampling time points. In most data sets, it was not possible to define a terminal elimination phase. The elimination rate constant was therefore not calculated, and exposure is reported as the AUC from time 0 to 24 h post-dosing (AUC0-24h). The AUC0-24h is chosen as it represents an intake interval of a daily intake of omega-3 supplement. Cmax was defined as the maximum observed plasma concentration. Plasma concentration below the limit of quantification was set to zero.

The pharmacokinetic analysis has been made on EPA and DHA, both with pre-existing endogenous levels. Therefore, the data should be evaluated corrected for pre-existing baseline levels. The endogenous concentrations of EPA and DHA are variable and can therefore contribute significantly to the total amount of EPA and DHA and would add to the inter- and intra-individual variability. We therefore conducted a pre-dose adjustment of measured levels. For each subject and test period, the pre-dose concentrations were subtracted from the measured plasma concentrations and the PK parameters was calculated on the baseline-adjusted concentrations according to regulatory guidelines for bioequivalence testing of endogenous substances [13, 14]. If the measured value was lower than the pre-dose concentration the adjusted concentration was set to zero. Some subjects having a result of 0 in baseline-corrected AUC due to malabsorption over the 0–24 h time window and hence the baseline-corrected concentration values were zero or below zero for almost the entire time window. These individuals were excluded from the ratio calculations as their individual ratios could not be calculated. If the baseline level was missing, the subject was excluded from the PK analysis for that period.

Statistical analyses

For both studies, the baseline corrected pharmacokinetic parameter data was provided to Covance CRU, Leeds, UK for further statistical analysis. The PK parameters were compiled including summary descriptive statistics (median, geometric mean with 90% confidence intervals (CI) and coefficient of variation (CV) arithmetic mean, standard deviation (SD) maximum and minimum values, and number of observations.

Statistical analysis was applied after dose normalization. The AUC0-24h, and Cmax parameters were dose-normalized by division of the administered corresponding fatty acid in grams.

Least squares (LS) means were calculated for dose normalized AUC0-24h and Cmax parameters for both formulations. Mean differences between PRF-021 and control formulations were calculated. Individuals with AUC0-24h levels below or equal to zero was excluded from the ratio calculations. The residual variance from the ANOVA was used to calculate 95% CI for the difference between treatments. These values were back-transformed to give geometric LS means, a point estimate and 95% CI for the ratio of PRF-021 to control.

All statistical analysis was pre-defined in the protocol or statistical plan for the studies.

Adverse events

No serious or significant adverse events assigned to treatment were reported in either group for both studies. PRF-021 was well tolerated by healthy subjects during the study. One subject was withdrawn from the Study 2 due to an adverse event of gout which was deemed not related to study supplement.

Results

Plasma concentrations of EPA plus DHA, and EPA and DHA individually, after single administration were significantly higher from PRF-021 vs. control despite lower doses of EPA and DHA.

Plasma concentrations of EPA and DHA following single oral administrations of either PRF-021 or control were measured with respect to two dosage levels in fasting subjects (Fig. 2). The endogenous baseline concentrations of plasma EPA and DHA are shown in Table 3.
Fig. 2

Sum of EPA + DHA concentration in plasma over time. Average value of sum of EPA + DHA concentration in plasma after a single oral dose of PRF-021 formulated Omega-3 EE or Control Omega-3 EE up to 48 h. (a) low dose Study 1, N = 20 (b) high dose Study 2, N = 39 for PRF-021 and N = 40 for Control

Table 3

Baseline plasma EPA and DHA concentration

Study

 

PRF-021 group mean ± SD (μg/mL)

Control group mean ± SD (μg/mL)

 1. Low dose

EPA

21.5 ± 11.2 (N = 20)

25.8 ± 14.6 (N = 20)

DHA

46.1 ± 16.7 (N = 20)

48.1 ± 15.2 (N = 20)

 2. High dose

EPA

23.6 ± 10.4 (N = 39a)

23.7 ± 9.79 (N = 40)

DHA

60.9 ± 18.4 (N = 39a)

61.2 ± 19.8 (N = 40)

aOne subject withdrawn

There were no statistically significant differences in the baseline EPA and DHA levels between the two treatment groups in both studies. Because the endogenous levels of EPA and DHA significantly influence the assessment of systemic exposure, the pre-dose concentrations of EPA and DHA were subtracted on an individual basis, and the PK analysis was performed on baseline-corrected data.

In Study 1, EPA and DHA in PRF-021 were given at lower dose levels, corresponding to those typically given by dietary supplement intake. Twenty individuals were given 840 mg of control EPA + DHA EE (1 g of control oil) and 630 mg of PRF-021 SMEDS formulated EPA + DHA EE (1.5 g of SMEDS formulation) in a cross-over design. Baseline corrected plasma concentration vs. time plots demonstrate that both EPA and DHA were significantly (p < 0.05) better absorbed by PRF-021 formulation vs. control (Fig. 3a), despite the absolute dosage of EPA + DHA in PRF-021 was only 75% of that of control.
Fig. 3

Baseline-corrected sum of EPA + DHA concentration in plasma over time. Average value of baseline-corrected sum of EPA + DHA concentration in plasma after a single oral dose of PRF-021 formulated Omega-3 EE or Control Omega-3 EE up to 48 h. (a) low dose Study 1, N = 20 (b) high dose Study 2, N = 39 for PRF-021 and N = 40 for Control

In the subsequent Study 2, the comparison was conducted at a higher dose range (1000–4000 mg of omega-3-acid EE). Forty participants were given 3360 mg of EPA plus DHA EE in control (4 g of control oil) and 1680 mg of EPA plus DHA EE in PRF-021 (4 g of SMEDS formulation) in a cross-over design. Though the latter had only 50% of the EPA + DHA dosage vs. the control, the concentration-time plots clearly showed much higher plasma concentrations versus that from control (Fig. 3b).

Dose-corrected pharmacokinetic parameters show 6- to 11-fold improvement in AUC0-24h dependent upon dose

Baseline corrected dose-normalized total EPA plus DHA exposure parameters are presented in Table 4. In Study 1, the formulated omega-3-acid EE had approximately 6-fold higher AUC0-24h, determined as geometric least square means after dose normalization. In study 2, the dose normalized difference between formulated and reference omega-3-acid EE oil was even bigger, 11 times for AUC0-24h.
Table 4

Baseline-corrected, dose normalized total EPA plus DHA AUC0-24h

Study

Treatment

Arithmetic mean ± SD of AUC0-24h/D

Geometric mean of AUC0-24h/D

Ratio of dose normalized geometric mean of AUC0-24h/Dc

μg*h/mL/g (N)

μg*h/mL/g (N)

N

Ratio PRF-021: Control

Lower 95% CI

Upper 95% CI

1

PRF-021

368.3 ± 156.4 (20)

331 (20)

19

6.2

4.3

9.0

Control

75.30 ± 57.50 (19b)

53.2 (19b)

2

PRF-021

358.3 ± 141.3 (39a)

331 (39a)

35

9.6

7.0

13.1

Control

46.96 ± 31.05 (36b)

35.7 (36b)

aOne subject withdrawn bSubject having a result of 0 was excluded cRatios calculated in subjects with complete dataset only

Both EPA and DHA absorption are increased by PRF-021 – The relative improvement is more pronounced with EPA

The absorption of EPA and DHA were also investigated individually (Fig. 4a-d). Plasma concentration of baseline corrected EPA or DHA concentrations vs. time data was plotted for both studies (Fig. 5a-d). After 1.5–2 h lag time, the EPA and DHA were absorbed into plasma reaching a maximum concentration at 4 and 8 h post dose. Plasma concentrations of individual fatty acids EPA (Fig. 5a and b) and DHA (Fig. 5c and d) were enhanced by PRF-021 vs. control despite lower dosing.
Fig. 4

EPA and DHA concentration in plasma over time. Average value of EPA and DHA concentration in plasma after a single oral dose of PRF-021 formulated Omega-3 EE or control Omega-3 EE up to 48 h with standard error bar (a) low dose Study 1, EPA, N = 20; (b) high dose Study 2, EPA, N = 39 for PRF-021 and N = 40 for Control; (c) low dose Study 1, DHA, N = 20 and (d) high dose Study 2, DHA, N = 39 for PRF-021 and N = 40 for Control

Fig. 5

Baseline-corrected EPA and DHA concentration in plasma over time. Average value of baseline-corrected EPA and DHA concentration in plasma after a single oral dose of PRF-021 formulated Omega-3 EE or control Omega-3 EE up to 48 h with standard error bar (a) low dose Study 1, EPA, N = 20; (b) high dose Study 2, EPA, N = 39 for PRF-021 and N = 40 for Control; (c) low dose Study 1, DHA, N = 20 and (d) high dose Study 2, DHA, N = 39 for PRF-021 and N = 40 for Control

Individual baseline-corrected dose-normalized EPA and DHA exposure pharmacokinetic parameters were presented in Tables 5 and 6, respectively. For EPA, PRF-021 exhibited a 7-fold higher Cmax and 24-fold higher AUC0-24h vs. control in Study 1 and a 9-fold higher Cmax and 26-fold higher AUC0-24h vs. control in Study 2. For DHA, Cmax was approximately 2.7-fold higher and AUC0-24h was 3.6-fold higher vs. control in Study 1 and Cmax and AUC0-24h were increased more by 4.3 and 5.6 times, respectively vs. control in Study 2. The relative absorption improvement is more pronounced for EPA than for DHA in both studies.
Table 5

Baseline-corrected dose normalized total EPA AUC0-24h and Cmax

Study

Treatment

Dose normalized parameter

Arithmetic Mean ± SD (N)

Geometric mean (N)

Ratio of dose normalized geometric meanc

N

Ratio PRF-021: Control

Lower 95% CI

Upper 95% CI

1

PRF-021

AUC0-24h/D μg*h/mL/g

355.9 ± 135.4 (20)

326 (20)

19

23.6

12.5

44.5

Control

33.4 ± 33.4 (19b)

13.7 (19b)

PRF-021

Cmax/D μg/mL/g

26.3 ± 9.8 (20)

25.9 (20)

19

6.7

5.0

9.0

Control

1.02 ± 5.6 (19b)

3.9 (19b)

2

PRF-021

AUC0-24h/D μg*h/mL/g

382.6 ± 122.6 (39a)

357 (39a)

35

25.58

15.9

41.1

Control

22.9 ± 20.1 (36b)

14.0 (36b)

PRF-021

Cmax/D μg/mL/g

20.9 ± 8.0 (39a)

24.5 (39a)

36

9.2

7.1

11.9

Control

1.5 ± 1.8 (40)

2.7 (40)

aOne subject withdrawn; bSubjects having a result of 0 was excluded cRatios calculated in subjects with complete dataset only

Table 6

Baseline-corrected dose normalized total DHA AUC0-24h and Cmax

Study

Treatment

Dose normalized parameter

Arithmetic mean ± SD (N)

Geometric mean (N)

Ratio of dose normalized geometric meanb

N

Ratio PRF-021: Control

Lower 95% CI

Upper 95% CI

1

PRF-021

AUC0-24h/D μg*h/mL/g

383.2 ± 202.8 (20)

325 (20)

20

3.63

2.57

5.14

Control

122.2 ± 93.10 (20)

89.5 (20)

PRF-021

Cmax/D μg/mL/g

33.4 ± 20.9 (20)

34.3 (20)

20

2.68

2.09

3.44

Control

7.95 ± 5.68 (20)

12.8 (20)

2

PRF-021

AUC0-24h/D μg*h/mL/g

328.9 ± 195.1 (39a)

266 (39)

39

5.61

3.97

7.92

Control

70.70 ± 53.88 (40)

48.1 (40)

PRF-021

Cmax/D μg/mL/g

28.2 ± 20.4 (39a)

36.4 (39a)

39

4.29

3.31

5.55

Control

3.88 ± 4.56 (40)

8.50 (40)

aOne subject withdrawn bRatios calculated in subjects with complete dataset only

Discussion

The current studies demonstrate that the application of Absorption Accelerating Technology a novel proprietary SMEDS technology, results in an increase of more than 6-fold in absorption as measured by ratios of baseline-adjusted, dose-normalized AUC0-24h of a single dietary supplement dose of total EPA + DHA in ethyl ester high concentrate in healthy fasting adults. These studies were designed to determine if absorption of EPA and DHA can be improved under a potential lowest-absorption scenario: Omega-3 ethyl ester consumed during fasting conditions. This report corroborates the result of a recent study which demonstrated a similar improvement in bioavailability from a micro-emulsified Omega-3 EE [15]. In contrast to Lopez-Toledano [15], this report demonstrated a quantitatively greater improvement in bioavailability due to fasted feeding conditions (the prior study was carried out with consumption of a low-fat meal – therefore inducing greater absorption of EE control). In this case, also the absorption improvement was verified for both a low and a high dose (with the lower dose targeting dietary supplement consumption) whereas the prior study featured a single, higher dose.

In this report the relative improvement of bioavailability is greater for EPA than for DHA. This result corresponds to a previous trial demonstrating greater absorption of single doses of Omega-3 ethyl esters under similar condition as the current study [16].

The relative bioavailability improvement for total EPA + DHA was greater under high dosage conditions (10-fold) versus low dosage (6-fold). This effect was primarily due to a relative change in absorption of DHA between the low and high dose studies (AUC0-24h ratio 3.6 and 5.6 respectively), whereas the ratio for EPA did not significantly change between the low and high dose cases. As the dose-adjusted AUC0-24h of DHA between the low-dose and high dose studies for PRF-021 are quantitatively similar, the difference in AUC ratio points to a difference in the dose-normalized DHA absorption of the control EE oils between low and high dose. This is indicative of a lower per mg absorption at higher doses for DHA (and thus a lower number in the denominator of the AUC ratio) due to limited digestive enzyme and emulsification activity in the fasted gut.

SMEDS-formulated Omega-3 EE utilizes a softgel containing a commonly available cost-effective Omega-3 ethyl ester format and has various advantages over current approaches to improve bioavailability. Ready-made oil-in-water emulsions formats increase single-dose absorption by factors of 1.3–1.5 over standard triglyceride fish oils [17, 18] but may have issues with oxidative stability and require liquid packet or spoonable delivery formats. Krill oil demonstrated a slight single dose absorption improvement of approximately 1.5X of standard fish oil [19, 20], but still require hydrolyzation by gut enzymes, in addition, the cost to gain clinically relevant EPA + DHA doses is significantly higher than fish oil-derived ethyl esters. Standard fish oil triglycerides have greater absorption of a single dose versus ethyl esters with a low-fat meal by a factor of approximately 3 [21] but also require consumption with meals as absorption is still limited by emulsification and digestion in the gut [22]. Omega-3 free-fatty acids (FFA)‘s demonstrated improved single-dose absorption in low-fat fed conditions over Omega-3 ethyl esters by up to a factor of 4 [16], however FFA’s are currently only widely available by prescription and require specialized formulation to reduce negative gastrointestinal effects of free fatty acids [16].

As this technology demonstrates bioavailability of Omega-3 in the condition of lowest expected absorption, at fasted stomach, it can be expected that bioavailability is assured regardless of stomach content. A recent study demonstrated that emulsified Omega-3 showed similar bioavailability in both low and high fat fed conditions [22]. This has potential benefit for those wishing to take supplements at early morning and late night occasions. Dietary surveys show that Americans consume only 16% of total fat in the morning for breakfast [23] – this means that for a large segment of the population breakfast is considered a “low fat” meal (<10 g fat). Average transit time of gastric emptying time is approximately 1–2 h [24], and as such, those that take dietary supplements at night before bed might also represent consumption on a nearly empty stomach. This technology is potentially beneficial to those consuming low-fat diets for health, age or medical reasons; for instance, those wishing to reduce caloric consumption, improve blood triglyceride levels, or improve risk of heart disease [25].

A key limitation of this study is the single-dose design at different dose levels. To conclusively verify a potential bioavailability benefit of this technology, further long-term studies are needed analysing the integration of EPA + DHA into tissue fatty acid content, eg. in erythrocytes [13, 26].

Conclusions

In conclusion, data from the two clinical studies demonstrate that the absorption of EPA + DHA EE in the SMEDS formulation was at least 6 greater than that of the reference omega-3-acid EE oil, determined by normalized AUC per gram of dose delivered. Individually, absorption increased at least by a factor of 23.6 for EPA and a factor of 3.6 for DHA. It is apparent that the absorption of Omega-3 EE is low in the fasted state and imperative that these supplements be taken with a fatty meal for appropriate absorption. Results from these two studies provide evidence of predictable increased absorption of EPA and DHA from the formulated product across the included intake range, without the need for a fatty meal.

Abbreviations

AUC: 

Area under the curve

BMI: 

Body mass index

CI: 

Confidence interval

Cmax

Maximum observed plasma concentration

CV: 

Coefficient of variance

D: 

Dose

DHA: 

Docosahexaenoic acid

EC: 

Ethics Committee

EE: 

Ethyl ester

EPA: 

Eicosapentaenoic acid

MHRA: 

Medical and Healthcare products Regulatory Agency

SD: 

Standard deviation

SMEDS: 

Self micro emulsifying delivery system

Declarations

Acknowledgments

We are grateful to Covance Clinical Research Unit AG, Basel, Switzerland, Principal Investigator Michael Seiberling, Covance Clinical Research Unit Ltd., Leeds, UK and the Principal Investigator Ashley Brooks for their study conduct, data analysis and data interpretation.

We are grateful to Per-Olof Larsson for his very valuable contribution to the studies.

Funding

Not applicable.

Availability of data and materials

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

Design of the study: YQ, EMH, SOH; conducts of the study: YQ, HN, EMH; data collection: YQ, HN; data analysis: YQ, SOH; data interpretation: YQ, HN, EMH, JMM, SOH; manuscript writing: YQ, JMM, SOH. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Study 1: Phase 1 study approval from Swissmedic, Bern, Reference Number 2012DR1071, Ethical Approval from Ethikkommission beider Basel. Study 2: Phase 1 study approval from MHRA, London, Reference Number, 15,905/0204/001–0001 EudraCT Number 2013–002375-18, Ethical Committee approval from NRES Committee South Central – Berkshire B, REC Reference 13/SC/0344.

Consent for publication

Not applicable.

Competing interests

The authors declare competing interests as employees of BASF.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Pronova Biopharma Norge AS, part of BASF
(2)
BASF Corporation

References

  1. Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, Franco OH, Butterworth AS, Forouhi NG, Thompson SG, Khaw KT, Mozaffarian D, Danesh J, Di Angelantonio E. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med. 2014 Mar 18;160(6):398–406.View ArticlePubMedGoogle Scholar
  2. Harris WS, Kris-Etherton PM, Harris KA. Intakes of long-chain omega-3 fatty acid associated with reduced risk for death from coronary heart disease in healthy adults. Curr Atheroscler Rep. 2008;10(6):503–9.View ArticlePubMedGoogle Scholar
  3. Wu JH, Marchioli R, Silletta MG, Macchia A, Song X, Siscovick DS, Harris WS, Masson S, Latini R, Albert C, Brown NJ, Lamarra M, Favaloro RR, Mozaffarian D. Plasma phospholipid omega-3 fatty acids and incidence of postoperative atrial fibrillation in the OPERA trial. J Am Heart Assoc. 2013;2(5):e000397.View ArticlePubMedPubMed CentralGoogle Scholar
  4. von Schacky C. Omega-3 index and cardiovascular health. Nutrients. 2014;6(2):799–814.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, Ma J. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002;346(15):1113–8.View ArticlePubMedGoogle Scholar
  6. Siscovick DS, Barringer TA, Fretts AM, Wu JH, Lichtenstein AH, Costello RB, Kris-Etherton PM, Jacobson TA, Engler MB, Alger HM, Appel LJ. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation. 2017;CIR-0000000000000482.Google Scholar
  7. Balk EM, Adam GP, Langberg V, Halladay C, Chung M, Lin L, Robertson S, Yip A, Steele D, Smith BT, Lau J, Lichtenstein AH, Trikalinos TA. Omega-3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review. Evidence Report/Technology Assessment No. 223. (Prepared by the Brown Evidence-based Practice Center under Contract No. 290–2015-00002-I.) AHRQ Publication No. 16-E002-EF. Rockville: Agency for Healthcare Research and Quality; 2016.Google Scholar
  8. Alexander DD, Miller PE, Van Elswyk ME, Kuratko CN, Bylsma LC. A meta-analysis of randomized controlled trials and prospective cohort studies of Eicosapentaenoic and Docosahexaenoic long-chain Omega-3 fatty acids and coronary heart disease risk. Mayo Clin Proc. 2017 Jan;92(1):15–29.View ArticlePubMedGoogle Scholar
  9. ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309–18.View ArticleGoogle Scholar
  10. Roncaglioni MC, Tombesi M, Avanzini F, Barlera S, Caimi V, Longoni P, Marzona I, Milani V, Silletta MG, Tognoni G, Marchioli R. N-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368(19):1800–8.View ArticlePubMedGoogle Scholar
  11. Schuchardt JP, Hahn A. Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2013 Jul;89(1):1–8.View ArticlePubMedGoogle Scholar
  12. Eckel RH, Jakicic JM, Ard JD, Hubbard VS, de Jesus JM, Lee IM, Lichtenstein AH, Loria CM, Millen BE, Miller NH, Nonas CA. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk. Circulation. 2013 Jan 1:01-cir.Google Scholar
  13. FDA, Draft Guidance on Omega-3-acid Ethyl Esters. 2012 Accessed July 1, 2017. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm320011.pdf
  14. European Medicines Agency, Guideline on the Investigation of Bioequivalence. 2010 Accessed July 1, 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf
  15. Lopez-Toledano MA, Thorsteinsson T, Daak A, Maki KC, Johns C, Rabinowicz AL, Sancilio FD. A novel ω-3 acid ethyl Ester formulation incorporating advanced lipid TechnologiesTM (ALT®) improves Docosahexaenoic acid and Eicosapentaenoic acid bioavailability compared with Lovaza®. Clin Ther. 2017 Mar;39(3):581–91.View ArticlePubMedGoogle Scholar
  16. Davidson MH, Johnson J, Rooney MW, Kyle ML, Kling DF. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study. J Clin Lipidol. 2012;6(6):573–84.View ArticlePubMedGoogle Scholar
  17. Lopez-Toledano MA, Thorsteinsson T, Daak A, Maki KC, Johns C, Rabinowicz AL, Sancilio FD, Minimal food effect for eicosapentaenoic acid and docosahexaenoic acid bioavailability from omega-3 acid ethyl esters with an Advanced Lipid TechnologiesTM (ALT®)-based formulation. J Clin Lipidol. 2017 in press.Google Scholar
  18. Garaiova I, Guschina IA, Plummer SF, Tang J, Wang D, Plummer NT. A randomised cross-over trial in healthy adults indicating improved absorption of omega-3 fatty acids by pre-emulsification. Nutr J. 2007;6:4.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Schuchardt JP, Schneider I, Meyer H, Neubronner J, von Schacky C, Hahn A. Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations--a comparative bioavailability study of fish oil vs. krill oil. Lipids Health Dis. 2011;10:145.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Köhler A, Sarkkinen E, Tapola N, Niskanen T, Bruheim I. Bioavailability of fatty acids from krill oil, krill meal and fish oil in healthy subjects--a randomized, single-dose, cross-over trial. Lipids Health Dis. 2015;14:19.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Lawson LD, Hughes BG. Absorption of eicosapentaenoic acid and docosahexaenoic acid from fish oil triacylglycerols or fish oil ethyl esters co-ingested with a high-fat meal. Biochem Biophys Res Commun. 1988;156(2):960–3.View ArticlePubMedGoogle Scholar
  22. Lawson LD, Hughes BG, Human absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl esters. Biochem Biophys Res Commun 1988;152(1):328-335.Google Scholar
  23. U.S. Department of Agriculture, Agricultural Research Service. 2016. Breakfast: Percentages of Selected Nutrients Contributed by Food and Beverages Consumed at Breakfast, by Gender and Age, What We Eat in America, NHANES 2013–2014.Google Scholar
  24. Vasavid P, et al. Normal solid gastric emptying values measured by scintigraphy using Asian-style meal: a multicenter study in healthy volunteers. J Neurogastroenterol Motility. 2014;20(3):371–8.View ArticleGoogle Scholar
  25. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease. Circulation. 2011;123(20):2292–333.View ArticlePubMedGoogle Scholar
  26. Maki KC, Johns C, Harris WS, Puder M, Freedman SD, Thorsteinsson T, Daak A, Rabinowicz AL, Sancilio FD. Bioequivalence demonstration for Ω-3 acid ethyl Ester formulations: rationale for modification of current guidance. Clin Ther. 2017;39(3):652–8.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement